|
ALBUQUERQUE, N.M.--(BUSINESS
WIRE)--Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD
- News) (www.biomoda.com)
and Obio, Inc., a corporation formed to pursue public and private
funding for cancer research in Ohio, are working together to
expand Biomoda’s lung cancer screening program for veterans into
Ohio.
“A strategic alliance
with Obio gives Biomoda a presence in a state that is recognized
as a leader in cancer research and treatment. Ohio’s leaders
have established programs and funding to attract promising
biomedical technologies to the state through innovative public
initiatives that support both research and commercialization,”
said John Cousins, President of Biomoda.
Biomoda currently is
conducting clinical trials of its CyPath® lung cancer diagnostic
assay, an inexpensive, noninvasive test designed to identify
early-stage lung cancer by binding to cancer cells and causing
them to fluoresce under ultraviolet light. Phase II trials have
focused on military veterans who are at least 25 percent more
likely to develop lung cancer and die from the disease.
Cousins said that Obio
will help Biomoda launch a veterans screening program in Ohio,
similar to ones completed in New
Mexico
and under consideration by the Nebraska Legislature. “We are
also identifying sites for the upcoming Phase III trials, and Ohio
is home to several world-class comprehensive cancer centers.”
Biomoda is seeking
Food and Drug Administration
(FDA) approval of its screening technology as a Class III medical
device. CyPath® is currently for investigational use only.
About
Biomoda
Biomoda
(OTC BB: BMOD) (www.biomoda.com)
is a cancer diagnostics company focused on the development of
accurate, inexpensive and noninvasive tests for the early
detection of cancer. Current research and development operations,
laboratory functions for both microscopy and assay formulation,
and administrative offices are located in Albuquerque, NM.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are based on
estimates, projections, beliefs and assumptions of Biomoda
management at the time of such statements and are not guarantees
of future performance. Forward-looking statements involve risks
and uncertainties in predicting future results and conditions.
Actual results could differ materially from those projected in
these forward-looking statements due to a variety of factors,
including, without limitation, the acceptance by customers of our
products, our ability to develop new products cost-effectively,
our ability to raise capital in the future, the development by
competitors of products using improved or alternative technology,
the retention of key employees and general economic conditions.
Forward-looking statements are made as of the date of this press
release and are subject to change without notice.
CONTACT:
Biomoda, Inc.
John
Cousins
505.821.0875
investor@biomoda.com
|
